Sunshine Biopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sunshine Biopharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 3.7 times its market value (net cash). Higher than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 43,354% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-7.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 52% of Healthcare companies in United States.
Cash Locked Ratio
$29For every $100 of sales, $29 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $37 from others' credit three years earlier.
More money tied up than 65% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$65Sales grew 735% in 3 years; of every extra $100 of sales, $65 became extra profit.
Higher than 74% of Healthcare companies in United States.
Asset Productivity Ratio
+735% / +3%In 3 years sales changed by +735% while total assets changed by +3%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-24.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 60% of Healthcare companies in United States.
Cash Cushion Ratio
3.7× cashCash, after subtracting all debt, is 3.7 times its market value (net cash).
Higher than 98% of Healthcare companies in United States.
Tangible Assets Ratio
94%Of every $100 the company owns, $94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 69% of Healthcare companies in United States.
Tangible Net Worth Ratio
92%Of every $100 of net worth, $92 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 75% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Sunshine Biopharma, Inc. made a loss over the last year. Sunshine Biopharma, Inc. owes $0.18 for every $1 it owns. Sunshine Biopharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSunshine Biopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.08The share price is 0.08 times Sunshine Biopharma, Inc.'s book value per share, lower than almost all Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Sunshine Biopharma, Inc.'s shares at today's price (share price × number of shares), smaller than 97% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$28 MWhat Sunshine Biopharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.86Net worth divided by the number of shares. The share price of $0.15 is 0.1 times this, which is the P/B above.
Return on equity (ROE)
-21.9%Sunshine Biopharma, Inc. lost 21.9% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
Owes vs Owns
0.18×Sunshine Biopharma, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Dividend yield
NoneSunshine Biopharma, Inc. does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and grew 103% a year on average over 3 years.
Profit growth
LossSunshine Biopharma, Inc. made a loss in each of the last two years.
Profit margin
-16.5%Sunshine Biopharma, Inc. lost $16 for every $100 of revenue.
Cash vs debt
Net cashSunshine Biopharma, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sunshine Biopharma, Inc.: $2 M ÷ $28 M (30 Jun 2026) = 0.1.
What is Sunshine Biopharma, Inc.'s return on equity?
Sunshine Biopharma, Inc. lost 21.9% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
How much does Sunshine Biopharma, Inc. owe compared with what it owns?
Sunshine Biopharma, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Does Sunshine Biopharma, Inc. pay a dividend?
No. Sunshine Biopharma, Inc. does not currently pay a dividend.
Is Sunshine Biopharma, Inc.'s revenue growing?
Revenue rose 4% in the year to Dec 2025, and grew 103% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.